title: Propranolol as a modulator of M2b monocytes in severely burned patients.
abstract: A role of immunosuppressive M2 monocytes (IL-12(-)IL-10(+)) on the increased susceptibility of severely burned patients to various opportunistic pathogens has been described. Among M2 monocyte subpopulations, M2b monocytes (IL-17(-)CCL1(+)CXCL13(-)) are predominantly present in the peripheral blood of severely burned patients. In the present study, the rise and fall of M2b monocytes were examined in severely burned patients treated with propranolol. Catecholamine is known as an inducer of M2 monocytes, and propranolol is a competitive blocker of catecholamine binding to β-adrenergic receptors. Twenty-two children with 30% or more TBSA burn were enrolled in the study. Propranolol at a dose of 4 mg/kg/day was administered to these patients by feeding-tube or mouth. Burn patient monocytes exhibited weak bactericidal activity. IL-12 was produced by propranolol-treated patient monocytes after stimulation with Staphylococcus aureus antigen, and the production of IL-10, CCL1, CCL17, or CXCL13 by these monocytes was not demonstrated. These results indicate that a predominance of M2b monocytes in severely burned patients is intervened by the propranolol treatment. The increased susceptibility, to be associated with the appearance of M2b monocytes, of severely burned patients to opportunistic pathogens might be controlled by propranolol.
authors.affiliation: Department of Internal Medicine, The University of Texas Medical Branch, Galveston, Texas 77555-0435, USA.
authors.forename: Makiko
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Marc G
authors.initials: MG
authors.lastname: Jeschke
authors.forename: Akira
authors.initials: A
authors.lastname: Asai
authors.forename: Mari
authors.initials: M
authors.lastname: Kogiso
authors.forename: Shohei
authors.initials: S
authors.lastname: Yoshida
authors.forename: David N
authors.initials: DN
authors.lastname: Herndon
authors.forename: Fujio
authors.initials: F
authors.lastname: Suzuki
mesh_terms: D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000942:Antigens, Bacterial / Q000378:metabolism; D002056:Burns / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D002395:Catecholamines / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007223:Infant; D016753:Interleukin-10 / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D020381:Interleukin-17 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D011433:Propranolol / Q000627:therapeutic use*; D011943:Receptors, Adrenergic, beta / Q000737:chemistry / Q000378:metabolism; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D013211:Staphylococcus aureus / Q000472:pathogenicity; D055815:Young Adult
chemical_list: D000319:Adrenergic beta-Antagonists; D000942:Antigens, Bacterial; D002395:Catecholamines; D020381:Interleukin-17; D011943:Receptors, Adrenergic, beta; D016753:Interleukin-10; D018664:Interleukin-12; D011433:Propranolol